Treats clinically important hypotension occurring in the setting of anesthesia. ANDA 212649, held by Dr Reddys. Ephedrine Sulfate.
As of Nov 16, 2026, ANDA 212649 (Ephedrine Sulfate), held by Dr Reddys, was first approved by FDA on Oct 3, 2020, with 1 approved supplement and 0 published complete response letters.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 3, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ephedrine Sulfate50MG/ML (50MG/ML) · solution;intravenous | Ephedrine Sulfate | Rx |
| Jun 30, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 3, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters